A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients  Stephen.

Slides:



Advertisements
Similar presentations
Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.
Advertisements

Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases Syed A. Ahmed, Karen Snow-Bailey, W. Edward Highsmith,
Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,
CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma
A Genome-Wide High-Resolution Array-CGH Analysis of Cutaneous Melanoma and Comparison of Array-CGH to FISH in Diagnostic Evaluation  Lu Wang, Mamta Rao,
Ane Y. Schmidt, Thomas v. O. Hansen, Lise B
Assessment of Target Enrichment Platforms Using Massively Parallel Sequencing for the Mutation Detection for Congenital Muscular Dystrophy  C. Alexander.
Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival 
Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers  Rebecca A. Betensky, Catherine.
Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data  Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.
Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes
Emily M. Kudalkar, Naif A. M
In Silico Proficiency Testing for Clinical Next-Generation Sequencing
Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes  Paula Paulo, Pedro.
Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses  Narasimhan Nagan, Nicole E. Faulkner,
The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients
Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario  Ricardo.
Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data  David H. Spencer,
Cystic Fibrosis The Journal of Molecular Diagnostics
Annotation of Sequence Variants in Cancer Samples
Comparison of High-Resolution Melting Analysis, TaqMan Allelic Discrimination Assay, and Sanger Sequencing for Clopidogrel Efficacy Genotyping in Routine.
William K. Funkhouser, Ira M. Lubin, Federico A. Monzon, Barbara A
Annotation of Sequence Variants in Cancer Samples
Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival  Ryan K. Van Laar 
A Clinical Grade Sequencing-Based Assay for CEBPA Mutation Testing
Cornelis J. J. Huijsmans, Jeroen Poodt, Paul H. M. Savelkoul, Mirjam H
Ken B. Waites, Li Xiao, Vanya Paralanov, Rose M. Viscardi, John I
Jacquelyn D. Riley, Gary W
Patrick R. Murray  The Journal of Molecular Diagnostics 
Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer  Daniel Trujillano, Maximilian.
The Impact on Genetic Testing of Mutational Patterns of CFTR Gene in Different Clinical Macrocategories of Cystic Fibrosis  Marco Lucarelli, Sabina M.
Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next- Generation Sequencing on a Four-Gene Panel  Ava Kwong, Vivian Y. Shin,
A Genome-Wide High-Resolution Array-CGH Analysis of Cutaneous Melanoma and Comparison of Array-CGH to FISH in Diagnostic Evaluation  Lu Wang, Mamta Rao,
Hillary S. Sloane, James P. Landers, Kimberly A. Kelly 
Somak Roy, Christopher Coldren, Arivarasan Karunamurthy, Nefize S
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies  Michael J. Kluk, R. Coleman Lindsley,
Jamal H. Carter, Samantha N. McNulty, Patrick J. Cimino, Catherine E
Marilyn M. Li, Michael Datto, Eric J
Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics  Maksym.
Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test  Bennett O.V. Shum, Ilya.
Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis.
BRAF Mutation Testing in Solid Tumors
Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma
The Molecular Pathology of Primary Immunodeficiencies
Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants.
Secondary Variants in Individuals Undergoing Exome Sequencing: Screening of 572 Individuals Identifies High-Penetrance Mutations in Cancer-Susceptibility.
Vida Kocbek, Katja Vouk, Nick A. Bersinger, Michael D
Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next- Generation Sequencing Panel Testing  Wenbo Mu, Hsiao-Mei Lu, Jefferey.
Jennifer A. Hempelmann, Sheena M. Scroggins, Colin C
Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next- Generation Sequencing Bioinformatics and Variant Interpretation  Kurtis.
Sarah E. Kerr, Cheryl B. Thomas, Stephen N. Thibodeau, Matthew J
Christoph Lange, Nan M. Laird  The American Journal of Human Genetics 
Genomic Technologies and the New Era of Genomic Medicine
Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma  Soo-Ryum Yang, Chieh-Yu Lin, Henning Stehr, Steven.
Multiple Sequence Variants in Hereditary Hemorrhagic Telangiectasia Cases  Jamie McDonald, Friederike Gedge, Allene Burdette, James Carlisle, Changkuoth.
Dale Muzzey, Shera Kash, Jillian I. Johnson, Laura M
Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers  Wenhsiang Wen, Wangjuh (Sting) Chen, Nick Xiao, Ryan.
Integration of Genomic Medicine into Pathology Residency Training
Variant Interpretation: Functional Assays to the Rescue
Use of Pyrosequencing of 16S rRNA Fragments to Differentiate between Bacteria Responsible for Neonatal Sepsis  Jeanne A. Jordan, Allyson R. Butchko, Mary.
Karen Snow-Bailey, Ph.D., 1961–2006
Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D
Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines 
The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests  Susan J. Hsiao, Mahesh M. Mansukhani,
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
Presentation transcript:

A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients  Stephen E. Lincoln, Yuya Kobayashi, Michael J. Anderson, Shan Yang, Andrea J. Desmond, Meredith A. Mills, Geoffrey B. Nilsen, Kevin B. Jacobs, Federico A. Monzon, Allison W. Kurian, James M. Ford, Leif W. Ellisen  The Journal of Molecular Diagnostics  Volume 17, Issue 5, Pages 533-544 (September 2015) DOI: 10.1016/j.jmoldx.2015.04.009 Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 Pathogenic variants by subpanel. Number of cases with pathogenic or likely pathogenic variants observed in BRCA1/BRCA2 and in 27 other genes (A) and in these 27 other genes by subpanel (B). The clinical referral cohort represents our best estimate of prevalence in a clinically representative population. The Journal of Molecular Diagnostics 2015 17, 533-544DOI: (10.1016/j.jmoldx.2015.04.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 Prevalence of variants of unknown significance (VUSs). Cumulative fraction of clinical cases with one or more VUSs reported, irrespective of pathogenic variants observed, as the scope of testing increases. The Journal of Molecular Diagnostics 2015 17, 533-544DOI: (10.1016/j.jmoldx.2015.04.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 3 Pathogenic variants by type. Pathogenic variants (n = 260) among the clinical cases (n = 1062) by variant type. A significant fraction (13.4%) of the pathogenic variants are of types known to be technically challenging for next-generation sequencing, even though they are a small fraction (<0.1%) of the total set of variants. Single-nucleotide variant (SNV) and copy number variant (CNV) are shown. The Journal of Molecular Diagnostics 2015 17, 533-544DOI: (10.1016/j.jmoldx.2015.04.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 4 Accumulation of new variants requiring interpretation. Accumulation of new variants in 29 genes requiring clinical interpretation as patients are added (n = 1062). The slope at the end is 0.7 new variants per patient. Variants with high minor-allele frequencies (>3% in the 1000 Genomes Project data) are automatically classified as benign and are not included in this analysis. Data shown are a smoothed average over 10 randomized orders of patients. The Journal of Molecular Diagnostics 2015 17, 533-544DOI: (10.1016/j.jmoldx.2015.04.009) Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions